Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis

• Published in: Oncotarget Vol. 7; no. 19; pp. 28139 - 28150
• Main Authors: Volpato, Milene, Perry, Sarah L, Marston, Gemma, Ingram, Nicola, Cockbain, Andrew J, Burghel, Heather, Mann, Jake, Lowes, David, Wilson, Erica, Droop, Alastair, Randerson-Moor, Juliette, Coletta, P Louise, Hull, Mark A
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 10.05.2016
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - blood; Chemokine CCL2 - blood; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Disease-Free Survival; Eicosapentaenoic Acid - therapeutic use; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Male; Mice; Mice, Inbred C57BL; Research Paper; Treatment Outcome; colorectal cancer; eicosapentaenoic acid and biomarker; prognosis; molecular pharmacology

The mechanism of the anti-colorectal cancer (CRC) activity of the omega-3 fatty acid eicosapentaenoic acid (EPA) is not understood. We tested the hypothesis that EPA reduces expression of chemokine C-C motif ligand 2 (CCL2), a pro-inflammatory chemokine with known roles in metastasis.We measured CCL...